|
Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC). |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche/Genentech |
Research Funding - Bayer; Eisai; Exelixis; Lilly; Merck Serono; Pfizer; Roche/Genentech; Xcovery |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - Exelixis; Genentech; GlaxoSmithKline; Lilly; Merck; Millennium; Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Sirtex Medical |
Speakers' Bureau - Genomic Health |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
No Relationships to Disclose |